Lung cancer and pregnancy

Sarıman, Nesrin; Levent, Ender; Yener, Neşe; Örkı, Alpay; Saygı, Attila

doi:10.1016/j.lungcan.2012.11.014

Cited by 29 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with TKIs may account for the improved outcomes seen in our series and recently published case reports. 15, 16, 17, 18, 19, 20 Indeed, most of the patients reported in our series are alive over 2 years after their lung cancer diagnosis (Table 3). Little, however, is known about the safety of targeted agents during pregnancy.…”

Section: Discussionmentioning

confidence: 80%

“…There are, however, two published cases of patients diagnosed with ALK- positive NSCLC during pregnancy/peripartum who were treated with crizotinib after delivery, in both cases after disease progression on chemotherapy. 19, 20 Reassuringly, review of the eight cases in our series suggests that for women diagnosed late in gestation, it may be possible to delay TKI treatment for a brief period until after delivery.…”

Section: Discussionmentioning

confidence: 81%

“…In contrast, the clinical outcomes of pregnant EGFR– mutant and ALK -positive NSCLC patients previously reported in the literature were comparable to those reported for non-pregnant patients. 15, 17, 19, 20 It is possible that the shorter PFS in this series may be confounded by additional factors, including diagnostic delays in two cases (case 6 and 8). Alternatively, a pregnancy/peripartum diagnosis of NSCLC may predispose to a particularly aggressive clinical course.…”

Section: Discussionmentioning

confidence: 96%

See 2 more Smart Citations

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

Dagogo‐Jack

Gainor

Porter

et al. 2016

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Background 1 in 1000 women will be diagnosed with cancer during pregnancy. The outcomes for non-small cell lung cancer (NSCLC) diagnosed during pregnancy are dismal, with most patients dying within one year. Actionable mutations are more likely to be found among younger patients with NSCLC. However, most previous reports of NSCLC diagnosed during pregnancy did not include molecular genotyping. Methods We performed a retrospective analysis of patients seen at our institution between 2009 and 2015 to identify women diagnosed with NSCLC during pregnancy or the peripartum period and determined clinicopathologic features, including molecular genotype. Results We identified 2,422 women with NSCLC, including 160 women of reproductive age. Among the women of reproductive age, eight cases of NSCLC diagnosed during pregnancy or the peripartum period were identified, all of whom were minimal or never-smokers with metastatic adenocarcinoma. Six of these patients were found to have ALK rearrangements, while the remaining two were EGFR mutation-positive. We observed a borderline significant association between a pregnancy/peripartum NSCLC diagnosis and ALK-positivity (p= 0.053). All eight women diagnosed with NSCLC during pregnancy/peripartum received treatment with genotype-directed therapies after delivery. The median overall survival (OS) has not been reached at a median follow-up of 30 months. Conclusions Although a pregnancy/peripartum diagnosis of NSCLC is rare, diagnostic evaluation should not be delayed in pregnant women presenting with symptoms worrisome for lung cancer. Evaluation should include testing for targetable molecular alterations.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

Dagogo‐Jack

Gainor

Porter

et al. 2016

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…We found 59 reports of lung cancer in pregnant women in the English literature. Among these, there were two reports of cancer harboring ALK fusion protein (3,4) and five of cancer harboring EGFR mutation (5-9) (Table I). At our hospital, to date we have encountered two cases of lung cancer diagnosed during pregnancy, including the present case.…”

Section: Discussionmentioning

confidence: 99%

A Case of a Pregnant Woman Diagnosed as HavingALK-rearranged Lung Adenocarcinoma

Komura

Yagishita

Nakamura

et al. 2018

In Vivo

View full text Add to dashboard Cite

A 28-year-old woman who was 34 weeks pregnant was admitted with complaints of cough and blood-stained sputum. After delivery of the baby at 37 weeks gestation, computed tomography and magnetic resonance imaging revealed a tumor in the right lung and a 15-mm brain metastasis. A diagnosis of lung adenocarcinoma was made, cT4N3M1b (stage IV disease) by pleural fluid cytology. Additional testing for anaplastic lymphoma kinase (ALK) fusion protein showed a strongly positive result, which was then confirmed by fluorescence in situ hybridization. The patient was started on treatment with alectinib, and the tumor and brain metastasis had almost vanished by 2 months after the start of this treatment. In the literature, there are 59 reports of lung cancer diagnosed during pregnancy, including two cases of cancer with expression of ALK fusion protein and five cases showing epidermal growth factor receptor mutation. The type of mutation should be taken into consideration while selecting for the appropriate therapeutic strategy.

show abstract

“…However, there have been reports of successful use of crizotinib for lung cancer in pregnancy. [ 13 ] Celecoxib is also considered a category C drug (Category D if used beyond 30 weeks of gestation) for use during pregnancy. Though steroids can be used safely in pregnancy, use in the first trimester has been associated with an increased risk of cleft lip.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory myofibroblastic tumor of the lung in pregnancy mimicking carcinoid tumor

2016

View full text Add to dashboard Cite

Inflammatory myofibroblastic tumors (IMT) are uncommon neoplasms of the lung in adults. They constitute less than 1% of all lung neoplasms and usually present as parenchymal masses. Diagnosis requires a high index of suspicion. They are characterized by spindle-shaped tumor cells (fibroblasts/myofibroblasts) in a background of lymphoplasmacytic infiltrate. About 50% of the tumors harbor an ALK gene rearrangement. They have to be differentiated from inflammatory pseudotumors (IPT), which show increased number of IgG4 plasma cells on immunostaining and are negative for anaplastic lymphoma kinase (ALK) protein. Herein, we present a case of a 28-year old female who presented with hemoptysis and was diagnosed with an IMT of lung in the first trimester of pregnancy. We have not only reviewed the occurrence of IMT during pregnancy but also discuss the management options for IMT during pregnancy.

show abstract

Lung cancer and pregnancy

Cited by 29 publications

References 9 publications

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

A Case of a Pregnant Woman Diagnosed as HavingALK-rearranged Lung Adenocarcinoma

Inflammatory myofibroblastic tumor of the lung in pregnancy mimicking carcinoid tumor

Contact Info

Product

Resources

About